Amgen milk peptides can ® and promote the double improvement of blood pressure and vascular endothelial.

Yao anti-Yuan Yu Shanghai Chengyi Food Raw Materials Co., Ltd
Anyi milk peptide
?
as a peptide substance that lowers blood pressure and regulates the endotoria of blood vessels, it has been in the Japanese market for a long time. Today, the anyi milk peptide market entering the Chinese ® is about to open up a new market.
hypertension is one of the most common cardiovascular diseases, so far, the number of people diagnosed with hypertension in China has exceeded 270 million people, hypertension has become one of the major health problems of public concern. However, when it comes to vascular endotoriasis, it is rarely known to be associated with atherosclerosis, high blood pressure, congestive heart failure, diabetes, high cholesterol and smoking. Recent studies have not only confirmed a clear relationship between endotinosis and coronary heart disease, but also showed that endotoriasis is an independent predictor of future cardiovascular events in patients with coronary heart disease and the earlyest change in atherosclerosis.
At present, there are many kinds of blood pressure-lowering drugs in circulation on the market, however, most of them have different degrees of side effects or use taboos, and for people with high blood pressure, mild hypertension alone lack a clear evidence of medication. It is worth mentioning that the improvement of vascular endoder function of these drugs is rarely mentioned, so much so that many vascular-related disease studies are carried out without attention, leading to complications.
in the general health care products product system, can meet the demand for buck products basically can not bypass a variety of flavonoid compounds, polyphenols and other plant extracts, product homogenization competition is serious. At the same time, due to Ginkgo, Gegen and other raw materials of different quality and sources, it is easy to affect the purity and quality of downstream products.
In recent years, the antihypertensives derived from cow cheese protein have become a new concern, and Asahi Kilbis of Japan has discovered peptides that can lower blood pressure in rats with high blood pressure during the use of L. Helveticus CP790 fermented milk. After mass spectrometry identification, it is determined that the key component sequence of the buck is the peptide segment of VPP-IPP, which can effectively inhibit the activity of ACE (angiotensin conversion enzyme). ACE plays an important role in the regulation of blood pressure in the human body: on the one hand, it promotes the transformation of angiotensin I to angiotensin II in the RAAS (renin-angiotensin-aldehyde solidone) system, which has a strong vasculature effect to promote hypertension; Therefore, when ACE is blocked by inhibitors, it affects vascular contractions and slow peptide degradation reactions are blocked, thus reducing blood pressure and dilating blood vessels. The ingredient is named Amea Pepide ® (Amea Milk Peptide ®).
studies have shown that amnix peptides® can also play a role in vascular dilation by stimulating vascular endothelial cells to produce NO and other substances. BaPWV is the speed of transmission of arm ankle pulse wave, is an effective response to vascular hardness of the key indicators, clinically through Omron's BP-203RPEII equipment can be detected. In a baPWV assay, the amniotic milk peptide ® increased the baPWV value by about 5% over an 8-week period, which improved the hardness index of this blood vessel. In addition, indicators of FMD (blood flow-dependent vascular dilation parameters) are considered to reflect vascular endoder function well. During an 8-week clinical observation, the indicator of amniotic peptides ® for FMD was improved by 22%, and the improvement range could be as high as 50% if combined with motor conditioning, so Ainyi milk peptides ® are considered to be ideal regulators of endothelial function of blood vessels. In the face of the majority of the domestic still to "soften blood vessels", "improve circulation" as a propaganda selling point of raw materials,
?
of blood vessel blood pressure, which is a clear stream for the market of raw materials for cardiovascular function.
currently, there are more than 50 scientific literatures on anyi milk peptide ® products, of which 12 clinical studies have carried out professional reports on their blood pressure reduction and improvement of the function of the vascular endothelial. Most valuablely, amgen peptides can ® effect on patients with high normal blood pressure and mild hypertension. From the use of the recommended amount of Ainyi milk peptides® on blood pressure levels, the average 4 weeks of blood pressure reduction range of up to 5/2mmHg, 6 weeks up to 9/4mmHg, 8 weeks of general buck range of up to 11/5mmHg. After doubling the dose, the time to achieve the same pressure reduction effect can be significantly shortened. Therefore, when it is necessary to quickly control blood pressure in the short term, consider appropriately increasing the daily dose. A few days ago, Amy milk peptides
?
clinically, strict safety trials have been conducted on over-use, and no significant side effects have been seen under the use of 8 times the recommended dose.
also used as a peptide anti-pressure raw material, the soybean peptide represented by plant protein has been shown to have significant blood pressure regulation function. However, a recent randomized controlled trial that looked at the effects of a three-month diet rich in soy protein and soy isoflavones on high blood pressure showed no positive changes in dynamic blood pressure within 24h, and another study also confirmed that there was no significant improvement in blood pressure and vascular function in people with high blood pressure who ate soy protein/soy flavonoids over a six-month period. Therefore, in the peptide raw material pressure reduction, milk protein sources of a beneficial milk peptides
?
because of its scientific and innovative characteristics, is constantly favored by the market.
in order to expand the scope and model of the application of Ainyi milk peptide ®, Asahi Kilbis Corporation of Japan has improved the production and preparation process of milk peptides. The current process uses food-grade proteases to efficiently and exclusively degrade milk beta casein, and then after inactivation, concentration, powdering and other processes, can accurately control the quality of the active ingredient in the final product, VPP-IPP.
in the Japanese market, the products with Ainyi milk ® as the main raw material have been tested by the market and have been thriving. Among them, "Ameal S" special health drinks listed in 1997 still firmly occupy the top position in the blood pressure beverage market, and "SHINAYAKACARE" listed in 2011 to fill the gap in the Japanese market for vascular health care. Through the expert publicity and media promotion of ® key raw material Anyi milk peptides, the rapid promotion of the market import period was completed, and the good feedback from consumers was obtained. Today, Anyi Milk Peptide ® has been listed in China, authorized Shanghai Chengyi Food Ingredients Co., Ltd. as China's only distributor, there is reason to believe that it will bring more opportunities to China's cardiovascular function raw materials market.
.